WO2010018563A3 - Compositions et procédés de pronostic d'un lymphome - Google Patents

Compositions et procédés de pronostic d'un lymphome Download PDF

Info

Publication number
WO2010018563A3
WO2010018563A3 PCT/IL2009/000764 IL2009000764W WO2010018563A3 WO 2010018563 A3 WO2010018563 A3 WO 2010018563A3 IL 2009000764 W IL2009000764 W IL 2009000764W WO 2010018563 A3 WO2010018563 A3 WO 2010018563A3
Authority
WO
WIPO (PCT)
Prior art keywords
prognosis
compositions
lymphoma
methods
derived
Prior art date
Application number
PCT/IL2009/000764
Other languages
English (en)
Other versions
WO2010018563A2 (fr
Inventor
Moshe Hoshen
Gila Lithwick Yanai
Meir Lahav
Ranit Aharonov
Original Assignee
Rosetta Genomics Ltd.
Mor Research Applications Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosetta Genomics Ltd., Mor Research Applications Ltd. filed Critical Rosetta Genomics Ltd.
Publication of WO2010018563A2 publication Critical patent/WO2010018563A2/fr
Publication of WO2010018563A3 publication Critical patent/WO2010018563A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des compositions et des procédés de pronostic d'un lymphome malin. Les compositions sont des molécules de micro-ARN associées au pronostic d'un lymphome, ainsi que diverses molécules d'acide nucléique liées à celles-ci ou dérivées de celles-ci.
PCT/IL2009/000764 2008-08-12 2009-08-05 Compositions et procédés de pronostic d'un lymphome WO2010018563A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8801508P 2008-08-12 2008-08-12
US61/088,015 2008-08-12

Publications (2)

Publication Number Publication Date
WO2010018563A2 WO2010018563A2 (fr) 2010-02-18
WO2010018563A3 true WO2010018563A3 (fr) 2010-04-15

Family

ID=41259376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2009/000764 WO2010018563A2 (fr) 2008-08-12 2009-08-05 Compositions et procédés de pronostic d'un lymphome

Country Status (1)

Country Link
WO (1) WO2010018563A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12037616B2 (en) 2023-02-28 2024-07-16 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4074834A1 (fr) 2012-11-26 2022-10-19 ModernaTX, Inc. Arn à terminaison modifiée
EP2931319B1 (fr) 2012-12-13 2019-08-21 ModernaTX, Inc. Molécules d'acide nucléique modifiées et leurs utilisations
JP2016504050A (ja) 2013-01-17 2016-02-12 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
WO2016077125A1 (fr) 2014-11-10 2016-05-19 Moderna Therapeutics, Inc. Molécules d'acide nucléique de remplacement contenant une quantité réduite d'uracile et utilisations associées
EP3405579A1 (fr) 2016-01-22 2018-11-28 Modernatx, Inc. Acides ribonucléiques messagers pour la production de polypeptides de liaison intracellulaires et leurs procédés d'utilisation
EP3443001A4 (fr) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. Systèmes de biocircuits régulés
MX2018013509A (es) 2016-05-18 2019-03-28 Modernatx Inc Polinucleotidos que codifican interleucina-12 (il12) y sus usos de los mismos.
WO2017218704A1 (fr) 2016-06-14 2017-12-21 Modernatx, Inc. Formulations stabilisées de nanoparticules lipidiques
WO2018002783A1 (fr) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Matériels et méthodes de traitement de l'ataxie de friedreich et d'autres troubles associés
WO2018002812A1 (fr) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Matériels et méthodes de traitement de la dystrophie myotonique de type 1 (dm1) et d'autres troubles associés
EP3478313B1 (fr) 2016-06-29 2022-05-04 CRISPR Therapeutics AG Matériaux et méthodes pour traiter la sclérose latérale amyotrophique (als) et d'autres troubles associés
JP2019520079A (ja) 2016-07-06 2019-07-18 クリスパー セラピューティクス アクチェンゲゼルシャフト 疼痛関連障害を処置するための物質及び方法
JP7305534B2 (ja) 2016-07-06 2023-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛関連障害を処置するための物質及び方法
AU2017347837A1 (en) 2016-10-26 2019-06-06 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
WO2018089540A1 (fr) 2016-11-08 2018-05-17 Modernatx, Inc. Formulations stabilisées de nanoparticules lipidiques
CA3051252A1 (fr) 2017-02-01 2018-08-09 Modernatx, Inc. Compositions therapeutiques immunomodulatrices d'arnm codant pour des peptides de mutation d'activation d'oncogenes
EP3585900B1 (fr) 2017-02-22 2022-12-21 CRISPR Therapeutics AG Matériels et méthodes de traitement d'ataxia spinocerebellaire de type 2 (sca2) et d'autres maladies ou de troubles liés au gene du protéine ataxia spinocerebellaire de type 2 (sca2)
EP3585899A1 (fr) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Matériaux et procédés pour le traitement de l'hyperoxalurie primitive de type 1 (ph1) et d'autres états ou troubles associés au gène de l'alanine glyoxylate aminotransférase (agxt)
CN110662838B (zh) 2017-02-22 2024-05-28 克里斯珀医疗股份公司 用于基因编辑的组合物和方法
WO2018154418A1 (fr) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Matériaux et procédés pour le traitement de la maladie de parkinson à début précoce (park1) et d'autres états pathologiques ou troubles associés au gène alpha (snca)
WO2018154439A1 (fr) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Matériaux et procédés pour le traitement de l'ataxie spinocérébelleuse de type 1 (sca1) et d'autres états ou troubles liés au gène de l'ataxie spinocérébelleuse de type 1 (atxn1)
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
CN111727251A (zh) 2017-11-21 2020-09-29 克里斯珀医疗股份公司 用于治疗常染色体显性色素性视网膜炎的材料和方法
EP3728594A1 (fr) 2017-12-21 2020-10-28 CRISPR Therapeutics AG Matériaux et méthodes de traitement du syndrome d'usher de type 2a
EP3728595A1 (fr) 2017-12-21 2020-10-28 CRISPR Therapeutics AG Substances et méthodes pour le traitement du syndrome d'usher de type 2a et/ou de la rétinite pigmentaire autosomique récessive (arrp) non syndromique
CA3089117A1 (fr) 2018-01-30 2019-08-08 Modernatx, Inc. Compositions et procedes destines a l'administration d'agents a des cellules immunitaires
EP3773745A1 (fr) 2018-04-11 2021-02-17 ModernaTX, Inc. Arn messager comprenant des éléments d'arn fonctionnels
EP3806888B1 (fr) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Constructions régulatrices dérivées de pde5 et procédés d'utilisation en immunothérapie
US20210378980A1 (en) 2018-09-20 2021-12-09 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
EP3870600A1 (fr) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Régulation de protéine accordable par er
WO2020160397A1 (fr) 2019-01-31 2020-08-06 Modernatx, Inc. Procédés de préparation de nanoparticules lipidiques
SG11202109172TA (en) 2019-03-08 2021-09-29 Obsidian Therapeutics Inc Human carbonic anhydrase 2 compositions and methods for tunable regulation
US20220387628A1 (en) 2019-06-24 2022-12-08 Modernatx, Inc. Messenger rna comprising functional rna elements and uses thereof
EP3987027A1 (fr) 2019-06-24 2022-04-27 ModernaTX, Inc. Arn messager résistant à l'endonucléase et utilisations correspondantes
WO2021046451A1 (fr) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions et méthodes de régulation de protéine accordable dhfr
BR112022014970A2 (pt) 2020-01-31 2022-09-20 Modernatx Inc Métodos para preparar nanopartículas lipídicas
EP4185274A1 (fr) 2020-07-24 2023-05-31 Strand Therapeutics Inc. Nanoparticule de nanoparticule lipidique comprenant des nucléotides modifiés
JP2023543963A (ja) 2020-08-06 2023-10-19 モデルナティエックス インコーポレイテッド 脂質ナノ粒子を調製する方法
JP2024503000A (ja) 2021-01-08 2024-01-24 ストランド セラピューティクス インコーポレイテッド 発現構築物およびその使用
EP4334446A1 (fr) 2021-05-03 2024-03-13 CureVac SE Séquence d'acide nucléique améliorée pour l'expression spécifique de type cellulaire
WO2023212618A1 (fr) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Nanoparticules lipidiques comprenant un réplicon d'encéphalite équine du vénézuela (vee) et leurs utilisations
WO2024026487A1 (fr) 2022-07-29 2024-02-01 Modernatx, Inc. Compositions de nanoparticules lipidiques comprenant des dérivés phospholipidiques et utilisations associées
WO2024026475A1 (fr) 2022-07-29 2024-02-01 Modernatx, Inc. Compositions pour administration à des cellules souches et progénitrices hématopoïétiques (hspc) et utilisations associées
WO2024026482A1 (fr) 2022-07-29 2024-02-01 Modernatx, Inc. Compositions de nanoparticules lipidiques comprenant des dérivés lipidiques de surface et utilisations associées

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105360A1 (en) * 2004-02-09 2006-05-18 Croce Carlo M Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features
EP1676914A1 (fr) * 2003-09-22 2006-07-05 Aichi Prefecture Type de lymphome pathologique et procede d'evaluation de diagnostic
US20070072204A1 (en) * 2005-05-02 2007-03-29 Hannon Gregory J Compositions and methods for cancer diagnosis and treatment
WO2007148235A2 (fr) * 2006-05-04 2007-12-27 Rosetta Genomics Ltd Acides nucléiques apparentés au cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1676914A1 (fr) * 2003-09-22 2006-07-05 Aichi Prefecture Type de lymphome pathologique et procede d'evaluation de diagnostic
US20060105360A1 (en) * 2004-02-09 2006-05-18 Croce Carlo M Diagnosis and treatment of cancers with microRNA located in or near cancer associated chromosomal features
US20070072204A1 (en) * 2005-05-02 2007-03-29 Hannon Gregory J Compositions and methods for cancer diagnosis and treatment
WO2007148235A2 (fr) * 2006-05-04 2007-12-27 Rosetta Genomics Ltd Acides nucléiques apparentés au cancer

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 841A, ISSN: 0006-4971 *
BLOOD, vol. 110, no. 11, Part 1, November 2007 (2007-11-01), 49TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 08 -11, 2007, pages 1049A, ISSN: 0006-4971 *
CALIN G A ET AL: "A MICRORNA SIGNATURE ASSOCIATED WITH PROGNOSIS AND PROGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 353, no. 17, 27 October 2005 (2005-10-27), pages 1793 - 1801, XP009058593, ISSN: 1533-4406 *
CALIN GEORGE A ET AL: "MicroRNA signatures in human cancers", NATURE REVIEWS. CANCER, NATUR PUBLISHING GROUP, LONDON, GB, vol. 6, no. 11, 1 November 2006 (2006-11-01), pages 857 - 866, XP002473506, ISSN: 1474-175X *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), LAWRIE CHARLES H ET AL: "MicroRNA expression profiling of diffuse large B-cell lymphoma reveals differences between germinal center-like and activated B cell-like subtypes.", XP002554909, Database accession no. PREV200600185370 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2007 (2007-11-01), ROBERTUS JAN-LUKAS ET AL: "Differences in the C13orf25 miRNA cluster in non-Hodgkin lymphoma and normal B-Cell subtypes", XP002554910, Database accession no. PREV200800218858 *
EIS P S ET AL: "Accumulation of miR-155 and BIC RNA in human B cell lymphomas", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 102, no. 10, 1 March 2005 (2005-03-01), pages 3627 - 3632, XP002396794, ISSN: 0027-8424 *
HE LIN ET AL: "A microRNA polycistron as a potential human oncogene", NATURE (LONDON), vol. 435, no. 7043, June 2005 (2005-06-01), pages 828 - 833, XP002554907, ISSN: 0028-0836 *
LAWRIE CHARLES H ET AL: "Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma", BRITISH JOURNAL OF HAEMATOLOGY,, vol. 141, no. 5, 3 March 2008 (2008-03-03), pages 672 - 675, XP002545705 *
LAWRIE CHARLES H ET AL: "MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma", INTERNATIONAL JOURNAL OF CANCER, vol. 121, no. 5, September 2007 (2007-09-01), pages 1156 - 1161, XP002554905, ISSN: 0020-7136 *
OTA A ET AL: "Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 64, no. 9, 1 May 2004 (2004-05-01), pages 3087 - 3095, XP002996247, ISSN: 0008-5472 *
ROEHLE ANJA ET AL: "MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas.", BRITISH JOURNAL OF HAEMATOLOGY SEP 2008, vol. 142, no. 5, 5 June 2008 (2008-06-05), pages 732 - 744, XP002554906, ISSN: 1365-2141 *
TAGAWA HIROYUKI ET AL: "Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development", CANCER SCIENCE, vol. 98, no. 9, September 2007 (2007-09-01), pages 1482 - 1490, XP002554908, ISSN: 1347-9032 *
TANZER A ET AL: "Molecular Evolution of a MicroRNA Cluster", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 339, no. 2, 28 May 2004 (2004-05-28), pages 327 - 335, XP004506520, ISSN: 0022-2836 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12037616B2 (en) 2023-02-28 2024-07-16 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions

Also Published As

Publication number Publication date
WO2010018563A2 (fr) 2010-02-18

Similar Documents

Publication Publication Date Title
WO2010018563A3 (fr) Compositions et procédés de pronostic d'un lymphome
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2009108866A3 (fr) Signatures en micro-arn associées à la cytogénétique et au pronostic dans la leucémie myéloïde aiguë (aml) et leurs utilisations
WO2009111643A3 (fr) Marqueurs microrna pour la récurrence d’un cancer colorectal
WO2010099161A8 (fr) Microarn chez les non-fumeurs et méthodes et matières apparentées
WO2009108860A3 (fr) Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate
WO2009061381A3 (fr) Variants d'alpha-amylase à propriétés modifiées
WO2009153775A3 (fr) Procédés permettant de différencier différents types de cancers du poumon
WO2009108217A3 (fr) Compositions comprenant un arnsi de k-ras et procédés d’utilisation
WO2007139723A8 (fr) Amorces d'oligonucléotides chimiquement modifiées pour l'amplification de l'acide nucléique
WO2007148235A3 (fr) Acides nucléiques apparentés au cancer
WO2010127304A3 (fr) Procédés de séquençage
WO2010048585A3 (fr) Composés oligomères et méthodes
HK1149950A1 (en) Novel compositions and related methods, coatings, and articles
WO2008069906A3 (fr) Expression numérisée de l'analyse génétique
WO2009012263A3 (fr) Micro-arn à spécificité cellulaire et compositions et utilisations de ces micro-arn
WO2008067423A3 (fr) Procédé d'amélioration de l'introduction d'adn dans des cellules bactériennes
WO2011156654A3 (fr) Caractérisation de voies de cellules
WO2009039189A3 (fr) Compositions comprenant des arnsi de stat3 et leurs procédés d'utilisation
WO2010045384A3 (fr) Arn courts en épingles à cheveux destinés à inhiber l’expression des gènes
WO2007014077A3 (fr) Modulation de l'arni du gene rho-a et utilisations de celle-ci
WO2009153774A3 (fr) Compositions et procédés pour le pronostic du cancer des ovaires
WO2011160052A3 (fr) Procédés et compositions associés à des arn-endonucléases spécifiques d'une séquence
WO2009135218A3 (fr) Détection de prédisposition génétique à des pathologies associées à l'arthrose
WO2009120712A3 (fr) Compositions et procédés pour diagnostiquer et traiter un mélanome

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09787509

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09787509

Country of ref document: EP

Kind code of ref document: A2